Whole Animal Angiogenesis ELISA for Drug Screening

描述（由申请人提供）：肿瘤组织血管发育通常 与胚胎血管发育和血管发育之间进行了比较 斑马鱼和哺乳动物的系统在分子水平上非常相似。使用 针对特定血管抗原的抗体，I期研究将 研究斑马鱼血管对血管生成抑制剂的反应， 建立了一种用于药物筛选的全动物血管生成ELISA方法。当前 用于研究血管生成的方法，组织操作使药物筛选 难斑马鱼是药物筛选的理想整体动物模型， 胚胎可以廉价地产生和维持， 自动分析。药物递送是简单的，并且药物和毒性作用是容易的。 因为胚胎是透明的，所以很容易被发现。快速胚胎 发展还有助于迅速检测药物作用。另外还有按 已经证明，参与脊椎动物血管生成的许多基因具有 同样的功能在斑马鱼身上。 拟定商业应用： 通过提供一种筛选药物对血管生成血管形成的作用的快速方法， 斑马鱼分析将促进用于多种疾病的药物开发过程， 包括癌症 癌症的治疗方法很多， 超过100亿美元的全球收入。 简化药物开发的分析， 临床需求量很大。

DESCRIPTION (provided by applicant): Tumor tissue vessel development has often been compared with embryonic vessel development, and vessel development between zebrafish and mammalian systems are very similar at the molecular level. Using antibodies against specific vascular antigens, Phase I research will investigate the response of zebrafish vessels to angiogenic inhibitors, and develop a whole animal angiogenesis ELISA for drug screening. In current methods used to study angiogenesis, tissue manipulation makes drug screening difficult. Zebrafish is an ideal whole animal model for drug screening because embryos can be generated and maintained inexpensively and are amenable to automated analysis. Drug delivery is simple, and drug and toxicity effects are easily detected because the embryos are transparent. Rapid embryonic development also facilitates rapid detection of drug effects. In addition, a number of genes involved in vertebrate angiogenesis have been shown to have the same function in zebrafish. PROPOSED COMMERCIAL APPLICATION: By providing a rapid method for screening durgs for effects on angiogenic vessel formation, the zebrafish assay will facilitate the drug development process for a variety of diseases, including cancer. Therapeutics approaches for cancer are numerous and generate in excess of $10B in worldwide revenue. Assays that streamline the drug development and clinical process are in high demand.